therascreen FGFR RGQ RT-PCR Kit by QIAGEN

Manufacturer QIAGEN
therascreen  FGFR RGQ RT-PCR Kit - For qualitative detection of actionable alterations in the FGFR3 gene.


therascreen FGFR RGQ RT-PCR Kit by QIAGEN product image
therascreen FGFR RGQ RT-PCR Kit
Request Pricing

Receive your quote directly from the manufacturer.



0 Scientists have reviewed this product


Write the First Review

No Reviews

For qualitative detection of actionable alterations in the FGFR3 gene

  • FDA-approved FGFR alteration assay
  • Detection of four point mutations and two fusions in the FGFR3 gene
  • High sensitivity and specificity
  • Simple workflow with next-day results
  • Automated data analysis using Rotor-Gene AssayManager v2.1 software

The therascreen FGFR RGQ RT-PCR Kit is a qualitative in vitro diagnostic test for the detection of two point mutations in exon 7 [p.R248C (c.742C>T), p.S249C (c.746C>G)], two point mutations in exon 10 [p.G370C (c.1108G>T) and p.Y373C (c.1118A>G)] and two fusions (FGFR3:TACC3v1 and FGFR3:TACC3v3) in the FGFR3 gene.

The therascreen FGFR RGQ RT-PCR Kit is the only FDA-approved companion diagnostic (CDx) test for the identification of patients with cases of urothelial cancer (UC) that harbor these actionable FGFR alterations, and for whom treatment with BALVERSA (erdafitinib) is indicated.

Product Overview

therascreen FGFR RGQ RT-PCR Kit by QIAGEN product image

therascreen FGFR RGQ RT-PCR Kit

Manufacturer QIAGEN

Be the first to review this product